ABIVAX_Logo-RGB.png
Abivax Announces a Change to the Composition of its Board of Directors
23. Dezember 2024 16:05 ET | Abivax
Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a...
ABIVAX_Logo-RGB.png
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
19. November 2024 16:30 ET | Abivax
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the...
Nurix.png
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
17. November 2024 10:30 ET | Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
ABIVAX_Logo-RGB.png
Abivax presents third quarter 2024 key financial information
14. November 2024 16:01 ET | Abivax
Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the...
ABIVAX_Logo-RGB.png
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
13. November 2024 16:01 ET | Abivax
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq:...
Nurix.png
Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
09. Oktober 2024 07:00 ET | Nurix Therapeutics, Inc.
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
ABIVAX_Logo-RGB.png
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
07. Oktober 2024 16:01 ET | Abivax
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation PARIS, France, October 7, 2024, 10:00...
ABIVAX_Logo-RGB.png
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
03. Oktober 2024 02:31 ET | Abivax
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated...
ABIVAX_Logo-RGB.png
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
26. September 2024 02:30 ET | Abivax
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and...
ABIVAX_Logo-RGB.png
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
25. September 2024 16:01 ET | Abivax
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease...